Insights into Chronic Obstructive Pulmonary Disease as Critical Risk Factor for Cardiovascular Disease

References

• (WHO) 1. World Health Organization. Chronic obstructive pulmonary disease (COPD). 1 December 2017. Key facts. Available from: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd). Accessed 722, 2019.
   Google Scholar
• VosT, AllenC, AroraM, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1545–1602. doi:10.1016/S0140-6736(16)31678-627733282
   PubMed Web of Science ®Google Scholar
• VanfleterenLEGW, SpruitMA, GroenenM, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(7):728–735. doi:10.1164/rccm.201209-1665OC23392440
   PubMed Web of Science ®Google Scholar
• SmithMC, WrobelJP. Epidemiology and clinical impact of major comorbidities in patients with COPD. Int J COPD. 2014;9:871–888. doi:10.2147/COPD.S49621
   Google Scholar
• YinHL, YinSQ, LinQY, XuY, XuHW, LiuT. Prevalence of comorbidities in chronic obstructive pulmonary disease patients. Med. 2017;96(19):e6836. doi:10.1097/MD.0000000000006836
   PubMed Web of Science ®Google Scholar
• ChenW, ThomasJ, SadatsafaviM, FitzGeraldJM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631–639. doi:10.1016/S2213-2600(15)00241-626208998
   PubMed Web of Science ®Google Scholar
• AlmagroP, López GarcíaF, CabreraFJ, et al. Study of the comorbidities in hospitalized patients due to decompensated chronic obstructive pulmonary disease attended in the Internal Medicine Services. ECCO Study. Rev Clin Esp. 2010;210(3):101–108. doi:10.1016/j.rce.2009.12.00220226938
   PubMed Web of Science ®Google Scholar
• AlmagroP, CabreraFJ, DiezJ, et al. Comorbidities and short-term prognosis in patients hospitalized for acute exacerbation of COPD: the EPOC en servicios de medicina interna (ESMI) study. Chest. 2012;142(5):1126–1133. doi:10.1378/chest.11-241323303399
   PubMed Web of Science ®Google Scholar
• MillerJ, EdwardsLD, AgustíA, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med. 2013;107(9):1376–1384. doi:10.1016/j.rmed.2013.05.00123791463
   PubMed Web of Science ®Google Scholar
• BoixedaR, Díez-ManglanoJ, Gómez-AntúnezM, López-GarcíaF, RecioJ, AlmagroP. Consensus for managing patients with chronic obstructive pulmonary disease according to the CODEX index. Rev Clin Esp. 2019;219(9):494–504. doi:10.1016/j.rce.2019.03.00631030885
   PubMed Web of Science ®Google Scholar
• AlmagroP, SorianoJBJB, CabreraFJFJ, et al. Short- and medium-term prognosis in patients hospitalized for COPD exacerbation: the CODEX index. Chest. 2014;145(5):972–980. doi:10.1378/chest.13-132824077342
   PubMed Web of Science ®Google Scholar
• DengD, ZhouA, PingC, ShuangQ. CODEXS: a new multidimensional index to better predict frequent COPD exacerbators with inclusion of depression score. Int J Chron Obstruct Pulmon Dis. 2020;2020:249–259. doi:10.2147/COPD.S237545
   Web of Science ®Google Scholar
• ArnettDKBR, AlbertMA, BurokerAB, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;74(10):e177–e232.
   Google Scholar
• KennedyBK, BergerSL, BrunetA, et al. Geroscience: linking aging to chronic disease. Cell. 2014;159(4):709–713. doi:10.1016/j.cell.2014.10.03925417146
   PubMed Web of Science ®Google Scholar
• ItoK, BarnesPJ. COPD as a disease of accelerated lung aging. Chest. 2009;135(1):173–180. doi:10.1378/chest.08-141919136405
   PubMed Web of Science ®Google Scholar
• BrandsmaC, Van den BergeM, HackettT, BrusselleG, TimensW. Recent advances in chronic obstructive pulmonary disease pathogenesis: from disease mechanisms to precision medicine. J Pathol. 2019. doi:10.1002/path.5364
   PubMed Web of Science ®Google Scholar
• SteenmanM, LandeG. Cardiac aging and heart disease in humans. Biophys Rev. 2017;9(2):131–137. doi:10.1007/s12551-017-0255-928510085
   PubMedGoogle Scholar
• FyhrquistF, SaijonmaaO, StrandbergT. The roles of senescence and telomere shortening in cardiovascular disease. Nat Rev Cardiol. 2013;10(5):274–283. doi:10.1038/nrcardio.2013.3023478256
   PubMed Web of Science ®Google Scholar
• NorthBJ, SinclairDA. The intersection between aging and cardiovascular disease. Circ Res. 2012;110(8):1097–1108. doi:10.1161/CIRCRESAHA.111.24687622499900
   PubMed Web of Science ®Google Scholar
• LiguoriI, RussoG, CurcioF, et al. Oxidative stress, aging, and diseases. Clin Interv Aging. 2018;13:757–772. doi:10.2147/CIA.S15851329731617
   PubMed Web of Science ®Google Scholar
• ZhuZ, WangX, LiX, et al. Genetic overlap of chronic obstructive pulmonary disease and cardiovascular disease-related traits: a large-scale genome-wide cross-trait analysis. Respir Res. 2019;20(1):64. doi:10.1186/s12931-019-1036-830940143
   PubMed Web of Science ®Google Scholar
• LangeP, CelliB, AgustíA, et al. Lung-function trajectories leading to chronic obstructive pulmonary disease. N Engl J Med. 2015;373(2):111–122. doi:10.1056/NEJMoa141153226154786
   PubMed Web of Science ®Google Scholar
• AgustíA, NoellG, BrugadaJ, FanerR. Lung function in early adulthood and health in later life: a transgenerational cohort analysis. Lancet Respir Med. 2017;5(12):935–945. doi:10.1016/S2213-2600(17)30434-429150410
   PubMed Web of Science ®Google Scholar
• FinksSW, RumbakMJ, SelfTH. Treating hypertension in chronic obstructive pulmonary disease. N Engl J Med. 2020;382(4):353–363. doi:10.1056/NEJMra180537731971680
   PubMed Web of Science ®Google Scholar
• KimSH, ParkJH, LeeJK, HeoEY, KimDK, ChungHS. Chronic obstructive pulmonary disease is independently associated with hypertension in men. Med. 2017;96(19):e6826. doi:10.1097/MD.0000000000006826
   PubMed Web of Science ®Google Scholar
• ManninoDM, ThornD, SwensenA, HolguinF. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32(4):962–969. doi:10.1183/09031936.0001240818579551
   PubMed Web of Science ®Google Scholar
• LamK-BH, JordanRE, JiangCQ, et al. Airflow obstruction and metabolic syndrome: the Guangzhou Biobank Cohort Study. Eur Respir J. 2010;35(2):317–323. doi:10.1183/09031936.0002470919574332
   PubMed Web of Science ®Google Scholar
• Cebron LipovecN, BeijersRJHCG, van den BorstB, DoehnerW, LainscakM, ScholsAMWJ. The Prevalence of metabolic syndrome in chronic obstructive pulmonary disease: a systematic review. COPD J Chronic Obstr Pulm Dis. 2016;13(3):399–406. doi:10.3109/15412555.2016.1140732
   PubMed Web of Science ®Google Scholar
• Diez-ManglanoJ, Barquero-RomeroJ, AlmagroP, et al. COPD patients with and without metabolic syndrome: clinical and functional differences. Intern Emerg Med. 2014;9(4):419–425. doi:10.1007/s11739-013-0945-723645508
   PubMed Web of Science ®Google Scholar
• SindenNJ, StockleyRA. Systemic inflammation and comorbidity in COPD: a result of “overspill” of inflammatory mediators from the lungs? Review of the evidence. Thorax. 2010;65(10):930–936. doi:10.1136/thx.2009.13026020627907
   PubMed Web of Science ®Google Scholar
• EapenMS, MyersS, WaltersEH, SohalSS. Airway inflammation in chronic obstructive pulmonary disease (COPD): a true paradox. Expert Rev Respir Med. 2017;11(10):827–839. doi:10.1080/17476348.2017.136076928743228
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Pulmonary Disease. 2020 GOLD Reports. 2020 Global strategy for prevention, diagnosis and management of COPD. Available from: https://goldcopd.org/gold-reports/. Accessed 223, 2020.
   Google Scholar
• KaptogeS, Di AngelantonioE, et al.; Emerging Risk Factors Collaboration. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367(14):1310–1320. doi:10.1056/NEJMoa110747723034020
   PubMed Web of Science ®Google Scholar
• KunisakiKM, DransfieldMT, AndersonJA, et al. Exacerbations of chronic obstructive pulmonary disease and cardiac events. a post hoc cohort analysis from the SUMMIT randomized clinical trial. Am J Respir Crit Care Med. 2018;198(1):51–57. doi:10.1164/rccm.201711-2239OC29442524
   PubMed Web of Science ®Google Scholar
• HarrisonMT, ShortP, WilliamsonPA, SinganayagamA, ChalmersJD, SchembriS. Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease: a role for antiplatelet therapy? Thorax. 2014;69(7):609–615. doi:10.1136/thoraxjnl-2013-20399624743560
   PubMed Web of Science ®Google Scholar
• Muñoz-EsquerreM, FerreiroJL, HuertasD, et al. Impact of acute exacerbations on platelet reactivity in chronic obstructive pulmonary disease patients. Int J COPD. 2018;13:141–148. doi:10.2147/COPD.S152660
   Google Scholar
• CampoG, PavasiniR, PollinaA, TebaldiM, FerrariR. On-treatment platelet reactivity in patients with chronic obstructive pulmonary disease undergoing percutaneous coronary intervention. Thorax. 2014;69(1):80–81. doi:10.1136/thoraxjnl-2013-20360823878160
   PubMed Web of Science ®Google Scholar
• PavasiniR, BiscagliaS, d’AscenzoF, et al. Antiplatelet treatment reduces all-cause mortality in COPD patients: a systematic review and meta-analysis. COPD. 2015;2555(January2016):1–6. doi:10.3109/15412555.2015.1099620
   Google Scholar
• ZemansRL, JacobsonS, KeeneJ, et al. Multiple biomarkers predict disease severity, progression and mortality in COPD. Respir Res. 2017;18(1):117. doi:10.1186/s12931-017-0597-728610627
   PubMed Web of Science ®Google Scholar
• SorensenGL. Surfactant protein D in respiratory and non-respiratory diseases. Front Med. 2018;5:18. doi:10.3389/fmed.2018.00018
   PubMed Web of Science ®Google Scholar
• HillJ, HeslopC, ManSFP, et al. Circulating surfactant protein-D and the risk of cardiovascular morbidity and mortality. Eur Heart J. 2011;32(15):1918–1925. doi:10.1093/eurheartj/ehr12421653561
   PubMed Web of Science ®Google Scholar
• LabontéLE, BourbeauJ, DaskalopoulouSS, et al. Club cell-16 and RelB as novel determinants of arterial stiffness in exacerbating COPD patients. PLoS One. 2016;11(2):e0149974. doi:10.1371/journal.pone.014997426914709
   PubMed Web of Science ®Google Scholar
• RabinovichRA, MillerBE, WrobelK, et al. Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD. Eur Respir J. 2016;47(5):1365–1373. doi:10.1183/13993003.01824-201527009168
   PubMed Web of Science ®Google Scholar
• BaumC, OjedaFM, WildPS, et al. Subclinical impairment of lung function is related to mild cardiac dysfunction and manifest heart failure in the general population. Int J Cardiol. 2016;218:298–304. doi:10.1016/j.ijcard.2016.05.03427240155
   PubMed Web of Science ®Google Scholar
• PavasiniR, TavazziG, BiscagliaS, et al. Amino terminal pro brain natriuretic peptide predicts all-cause mortality in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis. Chron Respir Dis. 2017;14(2):117–126. doi:10.1177/147997231667439327956645
   PubMed Web of Science ®Google Scholar
• PavasiniR, D’AscenzoF, CampoG, et al. Cardiac troponin elevation predicts all-cause mortality in patients with acute exacerbation of chronic obstructive pulmonary disease: systematic review and meta-analysis. Int J Cardiol. 2015;191:187–193. doi:10.1016/j.ijcard.2015.05.00625965630
   PubMed Web of Science ®Google Scholar
• PizarroC, Herweg-SteffensN, BuchenrothM, et al. Invasive coronary angiography in patients with acute exacerbated COPD and elevated plasma troponin. Int J Chron Obstruct Pulmon Dis. 2016;11:2081–2089. doi:10.2147/COPD.S11074627695304
   PubMedGoogle Scholar
• Ben-ShlomoY, SpearsM, BoustredC, et al. Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol. 2014;63(7):636–646. doi:10.1016/j.jacc.2013.09.06324239664
   PubMed Web of Science ®Google Scholar
• FiskM, McEnieryCM, GaleN, et al. Surrogate markers of cardiovascular risk and chronic obstructive pulmonary disease. Hypertension. 2018;71(3):499–506. doi:10.1161/HYPERTENSIONAHA.117.1015129358458
   PubMed Web of Science ®Google Scholar
• PatelARC, KowlessarBS, DonaldsonGC, et al. Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;188(9):1091–1099. doi:10.1164/rccm.201306-1170OC24033321
   PubMed Web of Science ®Google Scholar
• AlmagroP, AcostaE, NavarroA, MurilloMF, ValdivielsoS, de la SierraA. Study of arterial stiffness in patients with an acute coronary event and chronic obstructive pulmonary disease confirmed by spirometry. Rev Clin Esp. 2019;219(5):251–255. doi:10.1016/j.rce.2018.08.00730660321
   PubMed Web of Science ®Google Scholar
• HawkinsNM, PetrieMC, JhundPS, ChalmersGW, DunnFG, McMurrayJJV. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009;11(2):130–139. doi:10.1093/eurjhf/hfn01319168510
   PubMed Web of Science ®Google Scholar
• HeJ, OgdenLG, BazzanoLA, VupputuriS, LoriaC, WheltonPK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 2001;161(7):996–1002. doi:10.1001/archinte.161.7.99611295963
   PubMedGoogle Scholar
• RuttenFH, CramerM-JM, LammersJ-WJ, GrobbeeDE, HoesAW. Heart failure and chronic obstructive pulmonary disease: an ignored combination? Eur J Heart Fail. 2006;8(7):706–711. doi:10.1016/j.ejheart.2006.01.01016531114
   PubMed Web of Science ®Google Scholar
• MüllerovaH, AgustiA, ErqouS, MapelDW. Cardiovascular comorbidity in COPD: systematic literature review. Chest. 2013;144(4):1163–1178. doi:10.1378/chest.12-284723722528
   PubMed Web of Science ®Google Scholar
• FisherKA, StefanMS, DarlingC, LessardD, GoldbergRJ. Impact of COPD on the mortality and treatment of patients hospitalized with acute decompensated heart failure. The worcester heart failure study. Chest. 2015;147(3):637–645. doi:10.1378/chest.14-060725188234
   PubMed Web of Science ®Google Scholar
• de Miguel-díezJ, López-de-AndrésA, Hernández-BarreraV, et al. Influence of COPD on outcomes of patients hospitalized with heart failure: analysis of the Spanish National Hospital Discharge Database (2001–2015). Int J Cardiol. 2018;269:213–219. doi:10.1016/j.ijcard.2018.07.06730033345
   PubMed Web of Science ®Google Scholar
• KalhanR, MutharasanRK. Reducing readmissions in patients with both heart failure and COPD. Chest. 2018;154(5):1230–1238. doi:10.1016/j.chest.2018.06.00129908152
   PubMed Web of Science ®Google Scholar
• GreiverM, SullivanF, KaliaS, et al. Agreement between hospital and primary care on diagnostic labeling for COPD and heart failure in Toronto, Canada: a cross-sectional observational study. Npj Prim Care Respir Med. 2018;28(1):9. doi:10.1038/s41533-018-0076-829523779
   PubMed Web of Science ®Google Scholar
• BergerJS, SanbornTA, ShermanW, BrownDL. Effect of chronic obstructive pulmonary disease on survival of patients with coronary heart disease having percutaneous coronary intervention. Am J Cardiol. 2004;94(5):649–651. doi:10.1016/j.amjcard.2004.05.03415342301
   PubMed Web of Science ®Google Scholar
• CampoG, GuastarobaP, MarzocchiA, et al. Impact of COPD on long-term outcome after ST-segment elevation myocardial infarction receiving primary percutaneous coronary intervention. Chest. 2013;144(3):750–757. doi:10.1378/chest.12-231323392738
   PubMed Web of Science ®Google Scholar
• BundhunPK, GuptaC, XuGM. Major adverse cardiac events and mortality in chronic obstructive pulmonary disease following percutaneous coronary intervention: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2017;17(1):1–13. doi:10.1186/s12872-017-0622-228052754
   PubMed Web of Science ®Google Scholar
• AlmagroP, LapuenteA, ParejaJ, et al. Underdiagnosis and prognosis of chronic obstructive pulmonary disease after percutaneous coronary intervention: a prospective study. Int J Chron Obstruct Pulmon Dis. 2015;10:1353–1361. doi:10.2147/COPD.S8448226213464
   PubMed Web of Science ®Google Scholar
• FranssenFME, SorianoJB, RocheN, et al. Lung Function abnormalities in smokers with ischemic heart disease. Am J Respir Crit Care Med. 2016;194(5):568–576. doi:10.1164/rccm.201512-2480OC27442601
   PubMed Web of Science ®Google Scholar
• SorianoJB, RigoF, GuerreroD, et al. High prevalence of undiagnosed airflow limitation in patients with cardiovascular disease. Chest. 2010;137(2):333–340. doi:10.1378/chest.09-126419783666
   PubMed Web of Science ®Google Scholar
• RothnieKJ, YanR, SmeethL, QuintJK. Risk of myocardial infarction (MI) and death following MI in people with chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis. BMJ Open. 2015;5(9):e007824. doi:10.1136/bmjopen-2015-007824
   PubMed Web of Science ®Google Scholar
• RysiakE, ProkopI, ZarębaI, MrózRM. Estimates of medication expenditure for ischemic heart disease accompanying chronic obstructive pulmonary disease. Adv Exp Med Biol. 2018;1114:49–55. doi:10.1007/5584_2018_20129679364
   PubMed Web of Science ®Google Scholar
• SchwarzkopfL, WackerM, ErtlJ, HapfelmeierJ, LarischK, LeidlR. Impact of chronic ischemic heart disease on the health care costs of COPD patients - An analysis of German claims data. Respir Med. 2016;118:112–118. doi:10.1016/j.rmed.2016.08.00127578479
   PubMed Web of Science ®Google Scholar
• NilssonU, JohanssonB, ErikssonB, BlombergA, LundbäckB, LindbergA. Ischemic heart disease among subjects with and without chronic obstructive pulmonary disease–ECG-findings in a population-based cohort study. BMC Pulm Med. 2015;15(1):156. doi:10.1186/s12890-015-0149-126637314
   PubMed Web of Science ®Google Scholar
• NilssonU, BlombergA, JohanssonB, BackmanH, ErikssonB, LindbergA. Ischemic ECG abnormalities are associated with an increased risk for death among subjects with COPD, also among those without known heart disease. Int J Chron Obstruct Pulmon Dis. 2017;12:2507–2514. doi:10.2147/COPD.S13640428860744
   PubMed Web of Science ®Google Scholar
• RasmussenDB, BodtgerU, LambertsM, et al. Beta-blocker, aspirin, and statin usage after first-time myocardial infarction in patients with chronic obstructive pulmonary disease: a nationwide analysis from 1995 to 2015 in Denmark. Eur Heart J Qual Care Clin Outcomes. 2020;6(1):23–31. doi:10.1093/ehjqcco/qcy06330608575
   PubMed Web of Science ®Google Scholar
• RezaeiSS, RinnerC, RatajczakP, GrossmannW, GallW, WolztM. Use of beta-blocker is associated with lower mortality in patients with coronary artery disease with or without COPD. Clin Respir J. 2018;12(12):2627–2634. doi:10.1111/crj.1296830276967
   PubMed Web of Science ®Google Scholar
• AlmagroP, De la SierraA, AcostaE, et al. Spirometrically confirmed chronic obstructive pulmonary disease worsens long-term prognosis after percutaneous coronary intervention. Am J Respir Crit Care Med. 2018;197(6):824–826. doi:10.1164/rccm.201707-1389LE28885856
   PubMed Web of Science ®Google Scholar
• AboyansV, RiccoJB, BartelinkMLEL, et al. 2017 ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763–816. doi:10.1093/eurheartj/ehx09528886620
   PubMed Web of Science ®Google Scholar
• KaszubaM, ŚliwkaA, PilińskiR, et al. The comorbidity of chronic obstructive pulmonary disease and peripheral artery disease–a systematic review. COPD. 2019;16(3–4):292–302. doi:10.1080/15412555.2019.165327131581921
   PubMedGoogle Scholar
• LiaoKM, KuoLT, LuHY. Increased risk of peripheral arterial occlusive diseases in patients with chronic obstructive pulmonary disease: a nationwide study in Taiwan. Int J COPD. 2019;14:1455–1464. doi:10.2147/COPD.S202029
   Google Scholar
• McNicholasWT, VerbraeckenJ, MarinJM. Sleep disorders in COPD: the forgotten dimension. Eur Respir Rev. 2013;22(129):365–375. doi:10.1183/09059180.0000321323997063
   PubMedGoogle Scholar
• PeinadoVI, PizarroS, BarberàJA. Pulmonary vascular involvement in COPD. Chest. 2008;134(4):808–814. doi:10.1378/chest.08-082018842913
   PubMed Web of Science ®Google Scholar
• MaY, TongX, LiuY, LiuS, XiongH, FanH. ACE gene polymorphism is associated with COPD and COPD with pulmonary hypertension: a meta-analysis. Int J Chron Obstruct Pulmon Dis. 2018;13:2435–2446. doi:10.2147/COPD.S16877230147309
   PubMed Web of Science ®Google Scholar
• ChaouatA, NaeijeR, WeitzenblumE. Pulmonary hypertension in COPD. Eur Respir J. 2008;32(5):1371–1385. doi:10.1183/09031936.0001560818978137
   PubMed Web of Science ®Google Scholar
• GredicM, BlancoI, KovacsG, et al. Pulmonary hypertension in chronic obstructive pulmonary disease. Br J Pharmacol. 2020. doi:10.1111/bph.14979
   PubMed Web of Science ®Google Scholar
• KimYR, HwangIC, LeeYJ, HamEB, ParkDK, KimS. Stroke risk among patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Clinics (Sao Paulo). 2018;73. doi:10.6061/clinics/2018/e177
   Web of Science ®Google Scholar
• WindsorC, HerrettE, SmeethL, QuintJK. No association between exacerbation frequency and stroke in patients with COPD. Int J COPD. 2016;11:217–225. doi:10.2147/COPD.S95775
   Google Scholar
• LinCS, ShihCC, YehCC, et al. Risk of stroke and post-stroke adverse events in patients with exacerbations of chronic obstructive pulmonary disease. PLoS One. 2017;12(1):e0169429. doi:10.1371/journal.pone.016942928060955
   PubMed Web of Science ®Google Scholar
• LekoubouA, OvbiageleB. Prevalence and influence of chronic obstructive pulmonary disease on stroke outcomes in hospitalized stroke patients. eNeurologicalSci. 2017;6:21–24. doi:10.1016/j.ensci.2016.11.00728018982
   PubMedGoogle Scholar
• AlmagroP, SalvadóM, Garcia-VidalC, et al. Recent improvement in long-term survival after a COPD hospitalisation. Thorax. 2010;65(4):298–302. doi:10.1136/thx.2009.12481820388752
   PubMed Web of Science ®Google Scholar